Drug Profile
HEC 74647PA
Alternative Names: Antaitavir Hasophate; HEC-74647PALatest Information Update: 13 Jan 2023
Price :
$50
*
At a glance
- Originator Sunshine Lake Pharma
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Hepatitis C
Most Recent Events
- 02 Jan 2023 Sunshine Lake Pharma completes phase I trial in in healthy volunteers (NCT05446233)
- 01 Nov 2022 Sunshine Lake Pharma initiates a phase I pharmacokinetics trial (In volunteers) in China (PO, Suspension) (NCT05446233)
- 06 Jul 2022 Sunshine Lake Pharma plans a phase I trial in Hepatitis C (In volunteers) in China (PO, Suspension) in September 2022 (NCT05446233)